Table 3.
Plasma levels of inflammatory markers in control (n = 30) and treatment (n = 68) group at baseline and after 6 months.
| Inflammatory Marker | Group | Baseline | After 6 Months | p Value |
|---|---|---|---|---|
| hsCRP (mg/L) | Control | 0.80 (0.39–2.23) | 0.74 (0.35–1.47) | 0.713 |
| Treatment | 0.85 (0.36–1.81) | 0.79 (0.31–1.57) | 0.989 | |
| TNF-α (ng/L) | Control | 3.74 (2.99–5.02) | 3.91 (3.05–5.25) | 0.396 |
| Treatment | 3.91 (3.36–5.36) | 3.30 (2.53–6.04) | 0.402 | |
| IL6 (ng/L) | Control | 1.69 (1.19–2.18) | 1.69 (1.19–2.75) | 0.614 |
| Treatment | 1.69 (1.20–2.53) | 1.36 (1.16–2.18) | 0.066 | |
| IL8 (ng/L) | Control | 11.8 (10.8–16.1) | 11.5 (10.8–16.3) | 0.819 |
| Treatment | 13.5 (10.7–17.7) | 15.5 (10.8–24.1) | 0.250 |
hsCRP, high-sensitivity C-reactive protein; TNF-α, tumor necrosis factor-α; IL, interleukin. Data are presented as median and interquartile range (25–75%).